Johnson & Johnson Q3 Profit Declines on Competition

Johnson & Johnson (NYSE:JNJ) is reporting that its third-quarter profit declined 6.4% from the year-ago period.  The company cited increased expenditures related to marketing and competition from generics as the reason for its decline.

Net income declined to $3.2 billion or $1.15 per share.  The numbers for the year ago period were $3.42 billion in revenue and earnings per share of $1.23.  Adjusting for one-time expenses, earnings were $1.24.

Johnson & Johnson Earnings Cheat Sheet: Shrinking Margins for Fifth Consecutive Quarter, but Net Income Rises>>

Following is some information about Johnson & Johnson’s stock price performance, along with that of some of its competitors.

  • Johnson & Johnson (NYSE:JNJ): The shares recently traded at $63.92, up $0.11, or 0.17%, on the day.  The shares have traded in a 52-week range of $57.50 to $68.05 and its market capitalization is $175.09 billion.  About the company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets.  The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Pfizer, Inc. (NYSE:PFE): The shares recently traded at $18.63, down $0.06, or 0.32%, on the day.  The shares have traded in a 52-week range of $16.25 to $21.45 and its market capitalization is $145.35 billion.  About the company: Pfizer, Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals.  The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Merck & Co., Inc. (NYSE:MRK): The shares recently traded at $32.26, down $0.05, or 0.15%, on the day.  The shares have traded in a 52-week range of $29.47 to $37.6 and its market capitalization is $99.39 billion.  About the company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products.  Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Boston Scientific Corp. (NYSE:BSX): The shares recently traded at $5.50, down $0.05, or 0.9%, on the day.  The shares have traded in a 52-week range of $5.41 to $7.96 and its market capitalization is $8.42 billion.  About the company: Boston Scientific Corporation develops, manufactures, and markets minimally invasive medical devices.  The Company’s products are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology, gynecology and neuromodulation.
  • Abbott Laboratories (NYSE:ABT): The shares recently traded at $51.76, down $0.28, or 0.54%, on the day.  The shares have traded in a 52-week range of $45.07 to $54.24 and its market capitalization is $80.54 billion.  About the company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services.  The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products.  Abbott markets its products worldwide through affiliates and distributors.

(Note: Selected financial data are sourced from Google Finance.  All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>